Chronic treatment with haloperidol or fluphenazine decanoate: regional effects on dopamine and serotonin metabolism in primate brain.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002522:Chlorocebus aethiops; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D005476:Fluphenazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D012701:Serotonin / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D014446:Tyrosine 3-Monooxygenase; C011825:fluphenazine depot; D006220:Haloperidol; D005476:Fluphenazine; D004298:Dopamine; D006719:Homovanillic Acid